Peptides DB
Research-centric peptide and protocol reference hub
Study 10 of 33Erythropoietin (EPO) literaturebiorxiv-preprint · Observational2026

Transferrin receptor 1 binds human parvovirus B19 VP1u to facilitate entry

Transferrin receptor 1 (TfR1) has been identified as the receptor that facilitates the entry of human parvovirus B19 into erythroid progenitor cells.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the erythropoietin (epo) corpus
5
Preclinical
21
Observational · this one
1
Open-label
2
Randomised
4
Reviews

Summary and findings

This study investigates the interaction between human parvovirus B19 VP1 unique region (VP1u) and transferrin receptor 1 (TfR1) in erythroid progenitor cells. The research identifies TfR1 as the receptor facilitating B19V entry, confirmed through various binding assays and structural analysis. No therapeutic claims are made.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

<h4>Summary</h4> Human parvovirus B19 (B19V) exhibits a strict tropism for erythroid progenitor cells, which is governed by the VP1 unique region (VP1u). This region mediates cell-specific uptake by interacting with an unknown cellular receptor, termed VP1uR. Proximity labeling in permissive erythroid cells identified transferrin receptor 1 (TfR1/CD71) as the predominant membrane protein associated with VP1u. VP1u constructs colocalized with TfR1 at the cell surface of erythroid cells. Incubation with anti-TfR1 antibody OKT9 abolished binding and uptake of recombinant VP1u. While OKT9 efficiently inhibited B19V uptake and infection, it did not block virus binding to host cells. Direct binding assays confirmed interaction of VP1u to human TfR1. Using cryoEM we solved the 2.4 Å structure of the TfR1-VP1u complex, mapping the binding site and identifying the specific interactions. These findings establish TfR1 as the previously unknown receptor, VP1uR, required for B19V uptake.

Elsewhere in the Erythropoietin (EPO) corpus

DPrevalence and risk of cardiovascular events among people living with HIV: a meta-analysis.Annals of medicine · 2026 · Pooled prevalence of cardiovascular events was 6% (95% CI: 0.05-0.07).reviewBReal-world effectiveness of central dialysis fluid delivery system (CDDS) in maintenance hemodialysis: a retrospective multicenter study.Renal failure · 2026 · β = 3.50 g/L hemoglobin compared to SPDDS, p < 0.05HumanBImpaired fasting glucose is comparable to diabetes mellitus in predicting mortality and cardiovascular events in patients undergoing peritoneal dialysis: the role of β-cell function and insulin resistance.Renal failure · 2026 · n=216 · IFG independently predicted all-cause mortality (HR, 2.48; 95% CI, 1.16-5.32; p=0.02).HumanBThe relationship between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and tubular atrophy/interstitial fibrosis in patients with IgA nephropathy.Renal failure · 2026 · n=400 · NHHR was positively correlated with T lesions (r = 0.229, p < 0.001).HumanBAssociation Between Perioperative Daprodustat Use and Early Posttransplant Graft Function in Living Donor Kidney Transplantation: A Propensity Score-Matched Retrospective Study.Current therapeutic research, clinical and experimental · 2026 · n=64 · Week 1 estimated glomerular filtration rate: 53.3 ± 16.1 vs control 41.9 ± 17.9 mL/min/1.73 m²; P = 0.001HumanCAnalytical validation of an ultrasensitive multiplexed immunoassay for blood-based biomarkers GFAP, NF-L and taubiorxiv-preprint · 2026 · Intra-plate %CV averaged less than 10%.In vitro